Poor response to anti-anemia drug predicts higher risk of heart disease or death

Dec 29, 2010

Patients with diabetes, kidney disease and anemia who don't respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death, researchers at UT Southwestern Medical Center have found.

The results suggest that testing such patients' responsiveness to the drug and keeping blood iron levels a little low might reduce their risk, said Dr. Robert Toto, professor of internal medicine and clinical sciences and a senior author of the study, which appeared in the .

"These patients required higher doses and ended up having lower hemoglobin anyway," Dr. Toto said. "The results of this study might lead us in directions that can help."

The results were an unexpected finding of a study on darbepoetin alpha, which stimulates the production of red blood cells to counteract anemia. The drug, manufactured by Amgen, is sold under the name Aranesp.

The study, called the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) showed that darbepoetin alpha works no better than a placebo for improving cardiovascular and kidney outcomes, but it did lower the risk for and resulted in modest improvement in patient-reported outcomes among people with diabetes, kidney disease and anemia. However, people receiving darbepoetin alpha had nearly a twofold higher risk for stroke. Cancer deaths were also higher among people receiving the drug.

Darbepoetin alpha is one of a class of anti-anemia drugs that mimics erythropoietin, the body's natural hormone that stimulates production of red blood cells.

The combination of , and anemia affect about 1 million people in the U.S.

TREAT was a double-blinded experiment with a control group that received a placebo. It included 4,038 participants, all of whom had type 2 diabetes, anemia and kidney damage, although not enough to require dialysis. Of these, 1,872 received injections of the drug, and 1,889 received placebo injections.

Participants receiving darbepoetin alpha also received periodic subcutaneous injections of the drug with the aim of increasing their levels of hemoglobin – a protein in that carries oxygen – to a level of 13 grams per deciliter. If someone in the control group dropped to a dangerous hemoglobin level below 9 g/dl, he or she received "rescue therapy" with darbepoetin until the hemoglobin level returned to a level above 9 g/dl.

In analyzing the results, the researchers divided the participants into two groups: those whose hemoglobin levels promptly increased in response to early doses of darbepoetin alpha, and those whose bodies responded less strongly, with hemoglobin level staying low.

The participants who had poor initial responses to the drug had a higher rate of death, heart attack, stroke or heart failure, the researchers found.

The study cannot show whether those people had higher risk for those outcomes because they were in poorer health to begin with, or because of some action of the drug, the researchers stated.

However, it does raise the question of whether treatment for anemia should be customized according to a patient's response to the drug, Dr. Toto said.

"Our studies suggest that we might be able to use the initial dose response to identify high-risk groups in future studies," he said.

For instance, if a person's hemoglobin level doesn't improve within one or two months of anti-anemia treatment, it may be better to stop the drug and seek alternative treatment. A state of mild anemia might pose less cardiovascular risk in such a case than continuing or escalating the dose in an attempt to reach a normal hemoglobin level, Dr. Toto said. Conversely, for patients who respond quickly to the drug, treating them until they reach the normal goal range recommended by the Food and Drug Administration appears safer, he said.

Explore further: Hospitals should follow CDC recommendations for Ebola care

add to favorites email to friend print save as pdf

Related Stories

Anemia drug not helpful for kidney disease patients

Dec 22, 2009

An international study authored by a UT Southwestern Medical Center researcher has concluded that the anemia drug darbepoetin alfa works no better than a placebo in several other applications previously thought to be promising.

Recommended for you

West Africans get creative with Ebola awareness

1 hour ago

A young man on camera names the person who's challenged him to dump the contents of a bucket over his head. But in a twist on the ice bucket challenge, this man is soon drenched in frothy, soapy water—part ...

Canada pulling Ebola lab team from Sierra Leone

3 hours ago

Canada is evacuating a three-member mobile laboratory team from Sierra Leone after people in their hotel were diagnosed with Ebola. The World Health Organization earlier announced it is pulling a team out of the country.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

ironjustice
not rated yet Jan 02, 2011
If one knows how erythrocytosis works in relation to kidney disease. Erythropoietin goes DOWN when red blood cell are NOT 'required'. Erythrocytosis is KNOWN to causes diabetes. When there is too many red blood cells a common finding is too much iron in the body. This iron becomes UNAVAILABLE because the body has 'locked it away' / storage . When one adds erythropoietin UNLESS there is sufficient iron just 'floating around' then the erythropoietin will not be ABLE to turn on red blood cell production because not enough iron is AVAILABLE the erythropoietin cannot work BUT when vitamin C is infused it allows NOW the iron to be freed up for the erythropoietin to NOW turn the iron INTO red blood cells.
"Vitamin C alleviates resistance to erythropoietin in iron-overloaded patients"